Last updated: October 5, 2026
Quinapril hydrochloride/hydrochlorothiazide is a mature fixed-dose antihypertensive combination with limited branded value and no meaningful biologic or formulation exclusivity barrier. The commercial opportunity is concentrated in generic supply, reliable nitrosamine-controlled manufacturing, selective international markets, and differentiated dosage-form execution.
The principal risks are market contraction, historic nitrosamine recalls involving quinapril products, weak pricing power, and competition from newer antihypertensive combinations.
What is quinapril hydrochloride and hydrochlorothiazide?
Quinapril hydrochloride/hydrochlorothiazide combines an angiotensin-converting enzyme inhibitor with a thiazide diuretic.
| Parameter |
Quinapril hydrochloride/hydrochlorothiazide |
| Drug class |
ACE inhibitor plus thiazide diuretic |
| Primary indication |
Hypertension |
| Reference brand |
Accuretic |
| Original manufacturer |
Warner-Lambert, later Pfizer |
| FDA dosage strengths |
10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg historically marketed |
| Administration |
Oral tablet |
| Regulatory pathway |
Small-molecule NDA and ANDA |
| Biosimilar exposure |
None |
| Main commercial channel |
Generic prescription market |
| Key safety issue |
Nitrosamine impurity risk associated with quinapril products |
Quinapril is converted to the active metabolite quinaprilat. Hydrochlorothiazide increases sodium and water excretion. The combination addresses two complementary mechanisms, but it competes with widely available ACE inhibitor/thiazide combinations such as lisinopril/hydrochlorothiazide and enalapril/hydrochlorothiazide.
What is the FDA and Orange Book status of Accuretic?
Accuretic was approved under NDA 019909. Pfizer discontinued commercial distribution and recalled product in 2022 after testing identified nitrosamine impurity concerns in certain lots. FDA classified the product as discontinued for commercial reasons rather than as withdrawn from sale for safety or effectiveness reasons, a distinction relevant to generic approval under the Drug Price Competition and Patent Term Restoration Act.[1]
The Orange Book position is commercially favorable to generic applicants. The historic composition, active-ingredient, and formulation exclusivities for quinapril hydrochloride/hydrochlorothiazide have expired. No current unexpired Orange Book patent is generally understood to block an ANDA applicant from referencing the Accuretic product, subject to the applicable FDA listing and certification record at the time of filing.[2]
FDA regulatory milestones
| Event |
Approximate timing |
| Accuretic approval |
1989 |
| Generic quinapril/hydrochlorothiazide approvals |
2000s onward |
| Major generic-market maturity |
2010s |
| Pfizer Accuretic recall activity |
2022 |
| Current regulatory focus |
Product availability, nitrosamine control, and quality compliance |
The combination remains a conventional small-molecule tablet opportunity. It does not require a biosimilar pathway, complex-device review, or clinical efficacy redevelopment if an applicant can satisfy ANDA bioequivalence and quality requirements.
What patents protect quinapril hydrochloride and hydrochlorothiazide?
The core patent estate is effectively expired.
Quinapril was developed from ACE inhibitor chemistry protected by patents assigned to Warner-Lambert and related entities. Hydrochlorothiazide has been off patent for decades. The fixed-dose combination was marketed long enough that any meaningful U.S. composition, combination, or formulation exclusivity has expired.
| Patent category |
Current commercial relevance |
| Quinapril active-ingredient patents |
Expired |
| Hydrochlorothiazide patents |
Expired |
| Fixed-dose combination patents |
Expired |
| Tablet formulation patents |
Expired or nonblocking |
| Method-of-use patents |
Expired or commercially weak |
| Orange Book patent barrier |
No material current barrier expected |
| Manufacturing process patents |
Potentially relevant only if independently valid and enforceable |
A manufacturer should still conduct a freedom-to-operate review in each target jurisdiction. Expired U.S. patents do not establish freedom to operate in Europe, Japan, China, Canada, or other markets. Separate process, polymorph, impurity-control, or intermediate patents may exist outside the United States, although they are unlikely to create a durable barrier for a conventional generic tablet.
When does quinapril hydrochloride/hydrochlorothiazide lose exclusivity?
U.S. market exclusivity has already expired. The original product is a mature generic drug rather than an exclusivity-driven launch opportunity.
The practical exclusivity timeline is:
- Core quinapril and hydrochlorothiazide patent protection expired.
- The Accuretic reference product moved into a generic market.
- Any pediatric or regulatory exclusivity associated with the historic product has expired.
- Current commercial differentiation depends on supply, quality, formulation performance, and distribution rather than patent term.
A new applicant would generally pursue an ANDA supported by comparative dissolution and bioequivalence data. A Paragraph IV certification is unlikely to be commercially central unless a later-listed patent or jurisdiction-specific patent becomes relevant.
How many patents cover quinapril hydrochloride/hydrochlorothiazide?
The number of historical patents is greater than the number of patents with current blocking value. The relevant commercial conclusion is that no meaningful unexpired U.S. patent estate is expected to protect routine quinapril/hydrochlorothiazide tablets.
Patent analysis should separate:
- Historical compound patents.
- Expired fixed-dose combination patents.
- Expired formulation patents.
- Manufacturing or impurity-control patents.
- Later patents covering unrelated delivery systems or new combinations.
A patent search that counts every historical quinapril document can overstate competitive protection. For launch planning, the decisive question is whether a live patent can support an injunction or delay FDA approval. For the conventional immediate-release tablet, that risk appears low.
What excipients are used in quinapril hydrochloride/hydrochlorothiazide tablets?
Reference and generic formulations typically use conventional tablet excipients. Public labeling for quinapril/hydrochlorothiazide products identifies excipient classes that can include lactose, mannitol, magnesium carbonate, povidone, crospovidone or croscarmellose sodium, magnesium stearate, talc, colloidal silicon dioxide, gelatin, hydroxypropyl cellulose, titanium dioxide, and iron oxides.[3]
The exact qualitative and quantitative composition varies by manufacturer and strength.
Functional role of the main excipient classes
| Excipient class |
Formulation function |
Strategic consideration |
| Lactose or mannitol |
Diluent and mouthfeel modifier |
Manage moisture, compressibility, and patient tolerability |
| Magnesium carbonate |
Alkalizing or stabilizing component |
May influence quinapril stability and microenvironmental pH |
| Povidone or hydroxypropyl cellulose |
Binder |
Supports granule strength and tablet robustness |
| Crospovidone or croscarmellose sodium |
Disintegrant |
Controls tablet breakup and dissolution |
| Magnesium stearate |
Lubricant |
Excess use can slow wetting and dissolution |
| Colloidal silicon dioxide |
Glidant |
Improves powder flow and blend uniformity |
| Talc |
Processing aid or antiadherent |
Requires control for flow and content uniformity |
| Iron oxide |
Colorant |
Supports strength identification and product differentiation |
| Titanium dioxide |
Opacifier |
Regulatory status varies by jurisdiction |
The strongest formulation strategy is not a novel excipient claim. It is a robust, scalable composition that maintains dissolution similarity across strengths and protects quinapril from degradation during shelf life.
What excipient strategy best addresses nitrosamine risk?
Nitrosamine control should be the central technical workstream.
Quinapril contains structural features that require careful evaluation for nitrosamine formation and contamination. FDA has advised manufacturers to assess nitrosamine risk across active ingredients, excipients, water, solvents, packaging, and manufacturing conditions.[4]
A commercial formulation program should include:
- Supplier qualification for excipients and process chemicals.
- Testing for nitrite and nitrate contamination in excipients.
- Control of amines, nitrosating agents, and recycled solvents.
- Evaluation of water quality and cleaning residues.
- Control of granulation temperature, drying conditions, and hold times.
- Stability testing under long-term and accelerated conditions.
- Extractables and leachables assessment for packaging.
- A validated analytical method with low detection and quantitation limits.
- Lot-release and stability specifications aligned with current FDA expectations.
Excipients with variable nitrite content can create batch-to-batch risk even when the active pharmaceutical ingredient is controlled. A supplier with documented low-nitrite manufacturing and strong change-control systems can provide more value than a nominally cheaper excipient source.
Is an excipient-based patent strategy viable?
A new excipient combination could support a patent application only if it produces a credible technical effect, such as materially lower nitrosamine formation, improved dissolution stability, reduced degradation, or better content uniformity. Routine substitution of lactose, mannitol, povidone, or a disintegrant is unlikely to create durable patent value.
Potentially defensible technical areas include:
- A low-nitrite excipient system.
- A controlled-pH microenvironment for quinapril stability.
- A moisture-barrier tablet and packaging system.
- A manufacturing process that reduces nitrosamine formation.
- A modified-release formulation, if clinically and commercially justified.
- A fixed-dose tablet with improved dissolution consistency after storage.
These claims would face enablement, obviousness, and freedom-to-operate scrutiny. The commercial value would depend on whether the formulation solves a documented quality problem rather than merely using different inactive ingredients.
What commercial opportunities exist for generic manufacturers?
The main opportunity is a quality-led generic launch, not a premium branded product.
1. Reliable supply after recall-driven disruption
The 2022 recalls created an opening for manufacturers that can demonstrate consistent supply and defensible nitrosamine control. Wholesalers and health systems may favor suppliers with reliable release testing, redundant API sources, and transparent quality documentation.
2. Three-strength portfolio coverage
A complete portfolio covering 10/12.5 mg, 20/12.5 mg, and 20/25 mg can improve pharmacy substitution and contracting value. A single-strength launch has lower development cost but limited formulary relevance.
3. International registration
The product may retain demand in markets where ACE inhibitor/thiazide combinations remain standard therapy. Registration opportunities depend on local reference-product status, price controls, pharmacopoeial requirements, and whether quinapril remains included in treatment guidelines.
4. Contract manufacturing and licensing
Licensing opportunities are more likely to involve:
- ANDA ownership and manufacturing rights.
- Regional marketing rights.
- Technology transfer for low-nitrosamine production.
- API supply agreements.
- Packaging and serialization services.
- Private-label supply to pharmacy chains.
A royalty-bearing license based only on expired composition patents has limited value. A license supported by an approved ANDA, validated analytical package, or documented impurity-control process is more commercially credible.
What generic entry risks exist?
Generic entry risk is high because patents do not provide a meaningful barrier. The principal risks are operational and regulatory.
| Risk |
Impact |
| Nitrosamine failure |
Product recall, FDA action, supply interruption |
| API impurity variability |
Batch rejection and stability failure |
| Low market volume |
Limited return on development investment |
| Price erosion |
Rapid reduction in net selling price |
| Therapeutic substitution |
Loss of demand to lisinopril/HCTZ and ARB combinations |
| Supplier concentration |
Exposure to API or excipient shortages |
| Dissolution mismatch |
Bioequivalence failure or postapproval change burden |
| Low prescriber loyalty |
Limited branded differentiation |
An applicant should avoid assuming that historical approval guarantees easy reentry. FDA scrutiny of nitrosamines, process validation, and postmarket quality is higher than it was when many legacy products were first approved.
How does quinapril/hydrochlorothiazide compare with competing fixed-dose combinations?
| Product |
Commercial position |
Patent risk |
Clinical substitution risk |
| Quinapril/HCTZ |
Mature, disrupted by recalls |
Low |
High |
| Lisinopril/HCTZ |
Large, established generic market |
Low |
Direct substitute |
| Enalapril/HCTZ |
Mature generic combination |
Low |
Moderate |
| Losartan/HCTZ |
Broad use and strong generic presence |
Low |
High |
| Valsartan/HCTZ |
Established ARB combination |
Low |
High |
| Benazepril/HCTZ |
Smaller ACE inhibitor segment |
Low |
Moderate |
Quinapril/hydrochlorothiazide has no obvious therapeutic advantage sufficient to support premium pricing. Its commercial rationale depends on existing prescribing, regional demand, supply reliability, and payer acceptance.
What is the revenue exposure and market outlook?
Publicly available information does not support a reliable current standalone revenue estimate for quinapril/hydrochlorothiazide. Accuretic is no longer a major branded revenue product, and generic sales are fragmented across manufacturers and geographies.
The market outlook is characterized by:
- Low or declining average selling prices.
- Limited investment in physician promotion.
- High substitution by other ACE inhibitor and ARB combinations.
- Low switching costs for pharmacies and payers.
- Potential short-term supply opportunities after recalls.
- Greater value in manufacturing efficiency than in product branding.
A manufacturer should model the product as a low-to-moderate volume generic with high price sensitivity. The investment case improves if the company already has quinapril API access, an established antihypertensive sales force, or a portfolio of related fixed-dose combinations.
What litigation and Paragraph IV issues affect the product?
No major current U.S. patent litigation is expected to determine access to conventional quinapril/hydrochlorothiazide tablets. Because core patents are expired, a Paragraph IV strategy would have limited value unless a new patent is listed against a later-approved formulation or use.
The more important legal exposure concerns:
- Product liability after nitrosamine-related recalls.
- Manufacturing deviations.
- Failure to meet current impurity limits.
- False or incomplete regulatory submissions.
- Trademark use involving Accuretic or confusingly similar names.
- Contract disputes involving API, licensing, or supply commitments.
Settlement agreements are unlikely to be a major market-access factor for the legacy product. Generic applicants should still review FDA litigation records and Orange Book updates before submission.
Key Takeaways
- Quinapril hydrochloride/hydrochlorothiazide is a mature, off-patent fixed-dose antihypertensive combination.
- Accuretic is the historic reference brand, but Pfizer recall activity in 2022 weakened the branded commercial position.
- No meaningful unexpired U.S. patent barrier is expected for routine immediate-release tablets.
- Nitrosamine control is the central formulation, manufacturing, and regulatory issue.
- Conventional excipient substitution is unlikely to create strong patent value without a demonstrated technical effect.
- The most viable opportunity is a low-cost, high-quality generic with three-strength coverage and validated impurity control.
- Commercial upside is limited by price erosion and competition from lisinopril/hydrochlorothiazide, ARB/thiazide products, and other antihypertensive combinations.
- International and contract-manufacturing opportunities may be more attractive than a standalone U.S. branded launch.
FAQs
Is quinapril hydrochloride/hydrochlorothiazide still commercially available?
Generic products may remain available in selected markets, but availability varies by manufacturer, country, and supply status. The Accuretic brand experienced recall and discontinuation activity.
Can a company launch a generic quinapril/hydrochlorothiazide product without a Paragraph IV challenge?
Yes. With the core patent estate expired, an applicant would generally rely on an ANDA pathway and the applicable Orange Book certification rather than a patent-invalidity strategy.
Which excipients are most important for quinapril stability?
The most important formulation variables are the diluent system, alkalizing or buffering components, binder, disintegrant, lubricant level, moisture control, and packaging. Magnesium carbonate and low-nitrite excipient sourcing may be particularly relevant to stability and impurity management.
Is quinapril/hydrochlorothiazide subject to biosimilar competition?
No. It is a chemically synthesized small-molecule combination regulated through generic-drug pathways, not the biosimilar pathway.
Can a low-nitrosamine formulation receive new patent protection?
Potentially, but patentability depends on a demonstrated and non-obvious technical effect. A formulation that only replaces one routine excipient with another is unlikely to provide strong protection.
References
- U.S. Food and Drug Administration. (2022). Pfizer voluntarily recalls five lots of Accuretic tablets due to presence of nitrosamine impurity.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- DailyMed. (n.d.). Quinapril hydrochloride and hydrochlorothiazide tablets: Prescribing information. National Library of Medicine.
- U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry.
